Carriers of a genetic mutation show increased dependence on tobacco

Scientists at the Institut Pasteur, the French National Center for Scientific Research (CNRS) and Pierre and Marie Curie University (UPMC) have recently proven that, in mice, nicotine intake– nicotine is the main addictive substance in tobacco – is heavily regulated by a genetic mutation that is very common in humans. This mutation affects the neuronal nicotinic receptor, disrupting its function and resulting in partial inactivation of the "reward circuit". Carriers of this mutation therefore have to increase their consumption to feel the effects of tobacco. These results, published online on December 3, 2013 in Molecular Psychiatry, pave the way for the development of new smoking cessation treatments that target carriers of this mutation.

During , binds to , thus activating the "reward circuit", a neuronal system responsible for a number of responses – including a feeling of well-being – during normal function. The effect of nicotine on the brain compensates for withdrawal symptoms felt by smokers when they are deprived of tobacco. As a result, a person's tobacco consumption is closely linked to the sensitivity of these nicotinic receptors.

The teams led by Uwe Maskos, who heads the Integrative Neurobiology of Cholinergic Systems Unit at the Institut Pasteur / CNRS, and by CNRS scientist Philippe Faure, who manages the Neurobiology of Adaptive Processes laboratory (CNRS / UPMC), have recently made a discovery proving that nicotine addiction may be influenced by an individual's genetic heritage. These scientists show that, in mice, a genetic mutation resulted in a marked reduction in sensitivity to nicotine. Carriers of this gene therefore require a higher dose of tobacco than non-carriers in order to obtain the same amount of pleasure - somewhere on the order of three times more.

The mutation characterized by the scientists affects part of the nicotinic receptor. The presence of this mutation disrupts the normal function of the nicotinic receptor, partially inactivating the "reward circuit".

This mutation occurs frequently in humans. Other studies suggest that it is present in 35% of Europeans, and in nearly 90% of heavy smokers. These discoveries pave the way for the development of "personalized" smoking cessation treatments for individuals who carry this genetic mutation.

More information: Nicotine consumption is regulated by a human polymorphism in dopamine neurons, Molecular Psychiatry, December 3, 2013.

add to favorites email to friend print save as pdf

Related Stories

Internet addiction—Causes at the molecular level

Aug 29, 2012

Everybody is talking about Internet addiction. Medically, this phenomenon has not yet been as clearly described as nicotine or alcohol dependency. But a study conducted by researchers from the University of Bonn and the Central ...

Recommended for you

Despite risks, benzodiazepine use highest in older people

8 hours ago

Prescription use of benzodiazepines—a widely used class of sedative and anti-anxiety medications—increases steadily with age, despite the known risks for older people, according to a comprehensive analysis of benzodiazepine ...

Why some antidepressants may initially worsen symptoms

12 hours ago

New research helps explain a paradoxical effect of certain antidepressants—that they may actually worsen symptoms before helping patients feel better. The findings, highlighted in a paper publishing online December 17 in ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.